Revenue
2019
2020
2021
2022
2023
2024
2025
2026
Sonoma Pharmaceuticals, Inc. (SNOA)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2019
2020
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $14.3M | $12.7M | $13.3M | $12.6M | $18.6M | $17.9M | $19.0M | $16.7M | $12.8M | $9.4M | $13.9M | $13.7M | $15.5M | $12.7M | $9.8M |
| Gross profit | $7.4M | $5.5M | $4.7M | $4.5M | $4.0M | $6.6M | $8.1M | $8.9M | $7.3M | $5.7M | $2.6M | $7.3M | $8.4M | $10.7M | $8.7M | $6.1M |
| Research & development | $2.3M | $1.8M | $1.9M | $207,000 | $125,000 | $555,000 | $1.3M | $1.5M | $1.6M | $1.6M | $1.8M | $1.5M | $2.9M | $2.2M | $2.0M | $2.0M |
| Operating expenses | $9.9M | $9.2M | $9.4M | $9.0M | $9.9M | $10.0M | $15.5M | $20.1M | $21.5M | $18.6M | $17.4M | $13.9M | $14.4M | $14.1M | $15.2M | $13.6M |
| Operating income | −$2.5M | −$3.7M | −$4.7M | −$4.6M | −$5.9M | −$3.4M | −$7.4M | −$11.3M | −$14.2M | −$13.0M | −$14.7M | −$6.7M | −$6.1M | −$3.4M | −$6.5M | −$7.5M |
| EBITDAderived | −$2.3M | −$3.6M | −$4.5M | −$4.4M | −$5.7M | −$3.2M | −$7.1M | −$10.8M | −$13.7M | −$12.7M | −$14.5M | −$6.4M | −$5.8M | −$3.1M | −$6.1M | −$7.1M |
| Net income | −$3.2M | −$3.5M | −$4.8M | −$5.2M | −$5.1M | −$4.0M | −$3.3M | −$11.8M | −$14.3M | $9.3M | −$10.2M | −$8.2M | $3.7M | −$5.4M | −$7.3M | −$7.9M |
| Basic EPSper diluted share | -$1.89 | -$2.79 | -$10.63 | -$1.52 | -$1.92 | -$1.97 | -$2.24 | -$12.77 | -$28.49 | $2.20 | -$3.09 | -$0.85 | $0.54 | -$1.30 | -$1.87 | -$0.30 |
| Diluted EPSper diluted share | -$1.89 | -$2.79 | -$10.63 | -$1.52 | -$1.92 | -$1.97 | -$2.24 | -$12.77 | -$28.49 | $2.20 | -$3.09 | -$0.85 | $0.54 | -$1.30 | -$1.87 | -$0.30 |